Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2/3 study of zilovertamab vedotin plus standard therapy versus standard therapy in relapsed or refractory diffuse large B-cell lymphoma
MOH_2022-02-13_010486Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of zilovertamab vedotin in diffuse large B-cell lymphoma (DLBCL) (5 cohorts), sponsored by Merck & Co. Primary endpoints: Safety, Tolerability and 3 more. Started Oct 2021; status: completed.
02
Drugs
zilovertamab vedotin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on MOH_2022-02-13_010486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-02-13_010486.